Replimune Group Inc. has released the latest data on its candidate therapy Rp1 in combination with nivolumab, showing remarkable long-term survival benefits in patients with advanced melanoma who have developed resistance to PD-1 therapies, with a median overall survival of 32.9 months.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yen gains as Trump rules out Iran strikes before the midterms
SpaceX (SPCX.US) completes low-frequency spectrum allocation, targeting the entire US mobile communications market! The three major US telecom stocks plunge collectively after hours
SpaceX has reached an agreement to acquire a nationwide portfolio of low-band spectrum licenses for mobile communications, paving the way for its Starlink Mobile service to directly enter the U.S. telecommunications market.
Apple (AAPL.US) October Second Launch Event Incoming! First Touchscreen MacBook and New iPad mini Unveiled, M6 Chip and Smart Home Ecosystem Released Together
Apple (AAPL.US) is scheduled to launch a comprehensive new smart home strategy next week and plans to hold a second event in October to unveil its first touchscreen MacBook and the new iPad mini.
Pound holds its floor as BoE member Greene presses for a hike
Crypto prices
More
